Fundraising Fox
Capsida
Founded 2019 · 36 employees on LinkedIn · 2 known investors
Find your way into Capsida
Sign up to see every warm intro you have to Capsida
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Capsida team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Capsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids. The company targets both central nervous system and ophthalmology conditions across all ages.
Founders & leadership
Capsida was founded in 2019 by Viviana Gradinaru, Nick Goeden, Ph.D., and Nicholas Flytzanis.
Investors · 2
How we know: Westlake Village BioPartners's portfolio page · funding news · the VCSheet dataset · Not right? Tell us
Founder mafia
2 people who came through Capsida went on to found or lead other companies.
Related companies · 1
Companies working in the same space as Capsida.
In the news
Frequently asked questions
- What does Capsida do?
- Capsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids. The company targets both central nervous system and ophthalmology conditions across all ages.
- Who founded Capsida?
- Capsida was founded by Viviana Gradinaru, Nick Goeden, Ph.D., Nicholas Flytzanis in 2019.
- Who are Capsida's investors?
- Capsida's investors include Westlake Village BioPartners, Versant Ventures.